Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.

Genes, chromosomes & cancer - 1 Oct 2011

Boyd Kevin D, Ross Fiona M, Tapper William J, Chiecchio Laura, Dagrada GianPaolo, Konn Zoe J, Gonzalez David, Walker Brian A, Hockley Sarah L, Wardell Christopher P, Gregory Walter M, Child J Anthony, Jackson Graham H, Davies Faith E, Morgan Gareth J

Abstract excerpt

Hemizygous deletion of 17p (del(17p)) has been identified as a variable associated with poor prognosis in myeloma, although its impact in the context of thalidomide therapy is not well described. The clinical outcome of 85 myeloma patients with del(17p) treated in a clinical trial incorporating both conventional and thalidomide-based induction therapies was examined. The clinical impact of deletion, low...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetyltransferases
Share to Biomarkers, Pharmacological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromosomes, Human, Pair 17

Share to Hemizygote

Share to Multiple Myeloma

Share to Mutation Rate

Share to Thalidomide

Share to United Kingdom

Source

Identifiers

PMID: 21961181
DOI: 10.1002/gcc.20899

Genes

SAT2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.PMID 21961181Read ↗

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.Semantic proximity Read ↗

Mutations in TP53 are exclusively associated with del(17p) in multiple myelomaSemantic proximity Read ↗

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survivalSemantic proximity Read ↗

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.Semantic proximity Read ↗

Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.Semantic proximity Read ↗

p53 haploinsufficiency and functional abnormalities in multiple myeloma.Semantic proximity Read ↗

Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.Semantic proximity Read ↗

17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach.Semantic proximity Read ↗

Minor clone of del(17p) provides a reservoir for relapse in multiple myelomaSemantic proximity Read ↗

Presence of a p53 Gene Deletion in Patients With Multiple Myeloma Predicts for Short Survival After Conventional-Dose ChemotherapySemantic proximity Read ↗

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myelomaSemantic proximity Read ↗

Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.